Oleksandr Nevzghoda: Difference between revisions
Expand source-linked author records; preserve work-specific attribution |
Add complete multilingual reference and language navigation |
||
| Line 1: | Line 1: | ||
<div class="wiki-language-nav" style="padding:0.75em; border:1px solid #b5c8cd; border-radius:0.5em; margin-bottom:1em;">[[Oleksandr Nevzghoda|English]] · [[Oleksandr Nevzghoda/uk|Українська]] · [[Oleksandr Nevzghoda/es|Español]] · [[Oleksandr Nevzghoda/fr|Français]] · [[Oleksandr Nevzghoda/de|Deutsch]] · [[Oleksandr Nevzghoda/pt|Português]]</div> | |||
'''Oleksandr Nevzghoda''' is recorded as an author in the public publication source below. This is a publication-linked research record, not a complete biography. | '''Oleksandr Nevzghoda''' is recorded as an author in the public publication source below. This is a publication-linked research record, not a complete biography. | ||
Latest revision as of 00:52, 12 November 2026
Oleksandr Nevzghoda is recorded as an author in the public publication source below. This is a publication-linked research record, not a complete biography.
Documented work
Coauthor of the 2025 study of combined anti-tuberculosis medicines in Annals of Mechnikov’s Institute.
Research context: Content analysis of registered products, manufacturers and formulary coverage. The study design is not a clinical efficacy trial.
Named collaborators on this work: Alina Osyntseva, Valentyn Shapovalov, Iurii Titarenko, Viktoria Dovzhuk, Viktoriia Shapovalova, Valerii Shapovalov.
Inclusion records authorship of the cited work, not endorsement of every later Vision 2035 proposal. Publication affiliations are historical unless separately updated.
See People and attribution and Research network.